---
title: "Hinova: The new drug application for Dronedarone soft capsules has been approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242375122.md"
description: "According to the announcement from Hinova, the company's independently developed Class 1 new drug Haina'an® (generic name: Deutetrabenazine soft capsules) has been approved for marketing by the National Medical Products Administration. It is used for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after receiving abiraterone acetate and chemotherapy, and who have not previously received novel androgen receptor inhibitors"
datetime: "2025-05-29T10:33:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242375122.md)
  - [en](https://longbridge.com/en/news/242375122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242375122.md)
---

# Hinova: The new drug application for Dronedarone soft capsules has been approved

According to the Zhitong Finance APP, Hinova (688302.SH) announced that its independently developed Class 1 new drug Haina'an® (generic name: Deutetrabenazine soft capsules) has been approved for market launch by the National Medical Products Administration. It is used for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after receiving abiraterone acetate and chemotherapy, and who have not previously received novel androgen receptor inhibitors

### Related Stocks

- [688302.CN](https://longbridge.com/en/quote/688302.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [ANALYSIS-US small caps, consumer stocks, housing shares could bear brunt of yield spike](https://longbridge.com/en/news/286809229.md)
- [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md)
- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)